curacle co.,ltd. (KOSDAQ:365270)

South Korea · Delayed Price · Currency is KRW

10,410

-1,040 (-9.08%)

At close: Jun 26, 2026

92.42% (1Y)

Market Cap	248.62B +286.6%
Revenue (ttm)	1.06B -6.8%
Net Income	-17.13B
EPS	-947.23
Shares Out	21.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,909
Open	11,520
Previous Close	11,450
Day's Range	10,090 - 11,600
52-Week Range	3,600 - 20,750
Beta	2.03
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About curacle co.,ltd.

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- β/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combi... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2016

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 365270

Full Company Profile

Financial Performance

In 2025, curacle co.,ltd.'s revenue was 7.10 million, a decrease of -99.57% compared to the previous year's 1.63 billion. Losses were -18.11 billion, 21.7% more than in 2024.

Financial Statements